glp-1 mlm GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica GLP-1 Agonists: A Comprehensive Overview

Take our quiz

According to the available timelines, the phase 3 clinical trial is expected to conclude in early 2026 with potential FDA approval in 2027

Tirzepatide Is Sufficient (Stay Put) If: You're close to your target weight: If tirzepatide has gotten you 8090% of the way to your goal, switching drugs mid-course introduces titration disruption and new side effects for a marginal numerical gain

The better response is to build formats for a consumer who wants less volume, more control and clearer value from each eating occasion

PlexusDx eliminates this wait entirelypatients can begin injections the same week they enroll, with dose escalation handled directly by the clinical team without insurance delays